Griffin Constance A, Axilbund Jennifer E, Codori Ann Marie, Deise Ginny, May Betty, Pendergrass Cheryl, Tillery Miriam, Trimbath Jill D, Giardiello Francis M
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Fam Cancer. 2007;6(3):265-73. doi: 10.1007/s10689-007-9117-0. Epub 2007 Feb 17.
Ongoing advances in cancer genetics lead to new opportunities for early disease detection, predictive genetic testing and potential interventions. Limited information exists on patient preferences concerning recontact to provide updated information. We evaluated colon cancer genetics patient preferences concerning recontact about advances in medical genetics.
Information was mailed to 851 individuals seen at the Colon Cancer Risk Assessment Clinic at the Johns Hopkins Hospital and to participants in a colon cancer gene testing study seen during an 8-year period. Information provided included description of advances in gene testing technology, discovery of MSH6 and MYH genes, detailed fact sheets and a survey of patient preferences for notification and potential uses of new information.
Most patients wanted an ongoing relationship with genetics providers (63%), reinitiated by genetics providers (65%) and contact only with information specifically relevant to them (51%). Most preferred personalized letters as the means of contact (55%). Reasons for and against recontact and circumstances in which individuals would pursue additional genetic testing were also tabulated. There were few statistically significant differences in the responses between clinic and study participants.
Patients evaluated in a colon cancer risk assessment clinic want updated information at a rate similar to those who participated in a colon cancer gene testing study. These findings have implications for the consultative nonlongitudinal nature of such clinics and suggest patient preferences for personally-tailored information could be labor intensive.
癌症遗传学的不断进展为疾病早期检测、预测性基因检测和潜在干预带来了新机遇。关于患者对再次联系以获取最新信息的偏好,现有信息有限。我们评估了结肠癌遗传学患者对再次联系医学遗传学进展相关信息的偏好。
向在约翰霍普金斯医院结肠癌风险评估诊所就诊的851名个体以及在8年期间参与结肠癌基因检测研究的参与者邮寄了信息。提供的信息包括基因检测技术进展描述、MSH6和MYH基因的发现、详细情况说明书以及关于患者对通知的偏好和新信息潜在用途的调查。
大多数患者希望与遗传学服务提供者保持持续联系(63%),由遗传学服务提供者重新发起联系(65%),并且仅接触与他们具体相关的信息(51%)。大多数人更喜欢个性化信件作为联系方式(55%)。还列出了支持和反对再次联系的理由以及个体进行额外基因检测的情况。诊所参与者和研究参与者的回复在统计学上几乎没有显著差异。
在结肠癌风险评估诊所接受评估的患者希望获得最新信息的比例与参与结肠癌基因检测研究的患者相似。这些发现对这类诊所的咨询非纵向性质有影响,并表明患者对个性化信息的偏好可能需要大量人力。